Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Abstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with anti‐PD‐1 immune checkpoint inhibitors in combination w...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shuling Shi, Bingyan Li, Pengcheng Zhou, Linhui Chen, Huizhen Li, Yingyi Wang, Xiaoyu Deng, Qianqian Dang, Jingjing Wu, Boya Zha, Peihong Li, Yingjuan Zheng, Daoke Yang
Format:	Article
Language:	English
Published:	Wiley 2024-07-01
Series:	Cancer Medicine
Subjects:	immune checkpoint inhibitors immune‐related adverse events nasopharyngeal cancer PD‐1
Online Access:	https://doi.org/10.1002/cam4.7359
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune checkpoint inhibition in NPC: A comprehensive review of PD-L1 overexpression and treatment responses
by: Madhan Krishnan, et al.
Published: (2024-12-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)

PD-L1 mediated immune escape in nasopharyngeal carcinoma: Impact of LMP1 and IFN-γ on immune surveillance
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Challenges and advances of immune checkpoint therapy
by: Lingyu Li, et al.
Published: (2024-12-01)

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

Harnessing the Systemic Immunoinflammatory Index as a Potential Predictive Tool for Recurrent or Metastatic Nasopharyngeal Carcinoma Undergoing PD-L1 Inhibitor
by: Song G, et al.
Published: (2024-11-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs
by: Katarzyna Dziubek, et al.
Published: (2024-12-01)

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
by: Xiaoye Shi, et al.
Published: (2024-12-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

A new signature associated with anoikis predicts the outcome and immune infiltration in nasopharyngeal carcinoma
by: Yonglin Luo, et al.
Published: (2025-02-01)

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities
by: Hong Mu-Mosley, et al.
Published: (2024-12-01)

An overview of immune checkpoint inhibitor toxicities in bladder cancer
by: Avenie Mavadia, et al.
Published: (2024-12-01)

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model
by: Caroline Schoenherr, et al.
Published: (2025-01-01)

Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma
by: Shang K, et al.
Published: (2025-01-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response
by: Assia Hijazi, et al.
Published: (2023-12-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma
by: Liqianqi Chen, et al.
Published: (2025-01-01)

Overcoming immune evasion with innovative multi-target approaches for glioblastoma
by: Hai Su, et al.
Published: (2025-01-01)

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
by: Johannes M. Waldschmidt, et al.
Published: (2025-01-01)

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
by: Haozhe Cui, et al.
Published: (2024-11-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination
by: Kamran Kaveh, et al.
Published: (2021-10-01)

Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients
by: Lucile Dumolard, et al.
Published: (2025-01-01)

Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
by: Xiangyu Yin, et al.
Published: (2024-11-01)

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer
by: Sung Uk Bae, et al.
Published: (2025-03-01)

Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti‐pd‐1/pd-l1 therapy
by: Eda Alp, et al.
Published: (2024-12-01)

Effect of chemoradiotherapy on the dynamics of circulating lymphocyte subsets in patients with non-metastatic nasopharyngeal carcinoma
by: Lilan Yi, et al.
Published: (2025-02-01)

Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients
by: Alain Gelibter, et al.
Published: (2024-12-01)

KMO-driven metabolic reconfiguration and its impact on immune cell infiltration in nasopharyngeal carcinoma: a new avenue for immunotherapy
by: Nijun Chen, et al.
Published: (2025-02-01)

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
by: Fan Sun, et al.
Published: (2024-12-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01)

Association between history of viral infections and melanoma mortality
by: Nathan Shen, et al.
Published: (2024-11-01)